Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Single Nucleotide Polymorphisms-SNPs

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Port-site metastases after diagnostic laparoscopy in advanced ovarian cancer: a case report and a systematic review of the literature.

Frontiers in surgery·2026

Same author

Infliximab in a Child With Relapsing Tuberculous Meningoencephalitis: A Case Report and Literature Review.

The Pediatric infectious disease journal·2026

Same author

Detecting Gambling Addiction: How Text Mining of Customer-Operator Online Chats Reveals Behavioral Risks.

Journal of gambling studies·2026

Same author

Transforming clinical trials in rare genetic diseases through telemedicine.

Journal of community genetics·2026

Same author

Maternal Dietary Patterns, Socioeconomic Conditions, and Birth Outcomes in the MAMI-MED and Piccolipiù Italian Birth Cohorts.

Nutrients·2026

Same author

"EASY Study": A European, Prospective, Postmarket, Single-arm Study of Altis Single-incision Mini-sling for Female Stress Urinary Incontinence.

European urology focus·2026

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

No association between apolipoprotein E polymorphisms and recurrent pregnancy loss.

Sebastiano Bianca¹, Barbara Barrano, Nunzio Cutuli

¹Dipartimento Materno Infantile, Centro di Consulenza Genetica e di Teratologia della Riproduzione, Laboratorio di Citogenetica, ARNAS Garibaldi Nesima, Catania, Italy. sebastiano.bianca@tiscali.it

Fertility and Sterility

|September 8, 2009

Summary

This study found no link between APOE gene variations and recurrent pregnancy loss (RPL). Clinical decisions for RPL patients should not depend on APOE polymorphism status.

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Related Experiment Videos

Last Updated: Jun 20, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Area of Science:

Genetics
Reproductive Medicine
Human Physiology

Background:

Recurrent pregnancy loss (RPL) is a complex condition with various potential causes.
The apolipoprotein E (APOE) gene has been investigated for its potential role in reproductive outcomes.

Purpose of the Study:

To investigate the association between APOE gene polymorphisms and the risk of recurrent pregnancy loss.
To determine if APOE status influences clinical management strategies for RPL.

Main Methods:

Genotyping of APOE polymorphisms in a cohort of patients experiencing recurrent pregnancy loss.
Statistical analysis to assess the correlation between APOE variants and RPL incidence.

Main Results:

The study did not find significant evidence to support an association between APOE polymorphisms and recurrent pregnancy loss.
No correlation was observed between APOE genotype and the occurrence of RPL in the studied population.

Conclusions:

The findings do not support the previously reported association between APOE and RPL.
Clinical management of patients with recurrent pregnancy loss should not be guided by APOE polymorphism status.